26.10.2021 16:47

Factors Likely to Decide the Fate of AB InBev (BUD) in Q3

Anheuser-Busch InBev SA/NV BUD, also known as AB InBev, is slated to release third-quarter 2021 earnings on Oct 28. The leading alcohol beverage company is likely to register year-over-year revenue growth when it reports third-quarter 2021 results. The Zacks Consensus Estimate for AB InBev’s third-quarter revenues is pegged at $13.42 billion, suggesting 4.7% growth from the year-ago quarter.For third-quarter revenues, the consensus mark is pegged at 64 cents per share, suggesting a 19% decline from the prior-year reported figure. The consensus estimate has moved down 25.6% in the past 30 days.In the last reported quarter, the company delivered a negative earnings surprise of 21.5%. Its earnings missed the Zacks Consensus Estimate by 5.3%, on average, in the trailing four quarters.AnheuserBusch InBev SANV Price and EPS Surprise  AnheuserBusch InBev SANV price-eps-surprise | AnheuserBusch InBev SANV QuoteKey Factors to NoteAB InBev has been witnessing pressures from commodity cost inflation and adverse currency, which partly weighed on EBITDA. Negative transactional currency and higher commodity costs mainly related to increased aluminum and barley prices have been concerning.In the last reported quarter, management predicted the higher commodity costs environment to continue in the third quarter, exerting pressure on input costs. The company’s presence across various countries is likely to have exposed it to negative currency translations in the to-be-reported quarter.Higher SG&A expenses, attributed to increased variable compensation accruals and marketing investments, are also expected to have hurt the bottom line in the to-be-reported quarter.However, the company’s unique commercial strategy, strong brand portfolio, digital investments and operational excellence are likely to have aided market share growth across the majority of the key markets. This is expected to have partly cushioned the top and bottom lines in the to-be-reported quarter. Strength in the off-premise channel and premium brands, and investment in B2B platforms, e-commerce channels and digital marketing in the past few months have been the key growth drivers.Continued resilience in the global beer category is also expected to have aided the sales performance in the to-be-reported quarter.Zacks ModelOur proven model doesn’t conclusively predict an earnings beat for AB InBev this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat. But that’s not the case here. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.AB InBev has a Zacks Rank #5 and Earnings ESP of 0.00%.Stocks Poised to Beat Earnings EstimatesHere are some companies that you may want to consider as our model shows that these have the right combination of elements to deliver an earnings beat.Corteva, Inc. CTVA has an Earnings ESP of +7.89% and a Zacks Rank #3 at present. You can see the complete list of today’s Zacks #1 Rank stocks here.The Estee Lauder Companies Inc. EL currently has an Earnings ESP of +0.24% and a Zacks Rank #3.Tyson Foods, Inc. TSN has an Earnings ESP of +19.13% and a Zacks Rank #3 at present.More Stock News: This Is Bigger than the iPhone!It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 77 billion devices by 2025, creating a $1.3 trillion market.Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 4 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2022.Click here for the 4 trades >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report The Estee Lauder Companies Inc. (EL): Free Stock Analysis Report Tyson Foods, Inc. (TSN): Free Stock Analysis Report AnheuserBusch InBev SANV (BUD): Free Stock Analysis Report Corteva, Inc. (CTVA): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research
Weiter zum vollständigen Artikel bei "Zacks"
Quelle: Zacks

Nachrichten zu AB InBev SA-NV (Anheuser-Busch InBev)

  • Relevant
  • Alle
  • vom Unternehmen
  • Peer Group
  • ?

Um Ihnen die Übersicht über die große Anzahl an Nachrichten, die jeden Tag für ein Unternehmen erscheinen, etwas zu erleichtern, haben wir den Nachrichtenfeed in folgende Kategorien aufgeteilt:

Relevant: Nachrichten von ausgesuchten Quellen, die sich im Speziellen mit diesem Unternehmen befassen

Alle: Alle Nachrichten, die dieses Unternehmen betreffen. Z.B. auch Marktberichte die außerdem auch andere Unternehmen betreffen

vom Unternehmen: Nachrichten und Adhoc-Meldungen, die vom Unternehmen selbst veröffentlicht werden

Peer Group: Nachrichten von Unternehmen, die zur Peer Group gehören

Analysen zu AB InBev SA-NV (Anheuser-Busch InBev)

  • Alle
  • Buy
  • Hold
  • Sell
  • ?
23.11.2021AB InBev SA-NV (Anheuser-Busch InBev) OutperformBernstein Research
29.10.2021AB InBev SA-NV (Anheuser-Busch InBev) OverweightBarclays Capital
29.10.2021AB InBev SA-NV (Anheuser-Busch InBev) BuyDeutsche Bank AG
29.10.2021AB InBev SA-NV (Anheuser-Busch InBev) BuyJoh. Berenberg, Gossler & Co. KG (Berenberg Bank)
28.10.2021AB InBev SA-NV (Anheuser-Busch InBev) OutperformRBC Capital Markets

Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für AB InBev SA-NV (Anheuser-Busch InBev) nach folgenden Kriterien zu filtern.

Alle: Alle Empfehlungen

Buy: Kaufempfehlungen wie z.B. "kaufen" oder "buy"

Hold: Halten-Empfehlungen wie z.B. "halten" oder "neutral"

Sell: Verkaufsempfehlungn wie z.B. "verkaufen" oder "reduce"
mehr Analysen
Börse Stuttgart Anlegerclub

Heute im Fokus

US-Börsen schließen im Minus -- DAX geht tiefer ins Wochenende -- AstraZeneca erwägt wohl IPO der Impfstoffsparte -- Allianz verspricht Dividendenwachstum -- Tesla, DiDi, Aurubis, Daimler im Fokus

Porsche SE verlängert Pötsch-Vorstandsmandat. Walgreens Boots Alliance prüft wohl Verkauf von britischer Tochter Boots. BioNTech-Chef erwartet Notwendigkeit von neuem Impfstoff. Nordex sichert sich Großauftrag. US-Jobwachstum gerät im November überraschend ins Stocken. VW senkt Absatzziel für ID-Elektromodelle in China.


Wie bewerten Sie die Verhandlungsergebnisse und künftigen Pläne der Ampelkoalition?

finanzen.net zero
finanzen.net zero



Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.
Zur klassischen Ansicht wechseln